Disease Activity

Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study
Alain Saraux, René-Marc Flipo, Francis Fagnani, Jacques Massol, Gabrielle Cukierman, Jean-Michel Joubert, Philippe Huot-Marchand, Bernard Combe

RMD Open Jan 2020, 6 (1) e000991; DOI: 10.1136/rmdopen-2019-000991
Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice
Niels W Boone, Alexandre Sepriano, Paul-Hugo van der Kuy, Rob Janknegt, Ralph Peeters, Robert B M Landewé

RMD Open Nov 2019, 5 (2) e001050; DOI: 10.1136/rmdopen-2019-001050
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
Gerd R Burmester, Vibeke Strand, Andrea Rubbert-Roth, Howard Amital, Tatiana Raskina, Antonio Gómez-Centeno, Claudia Pena-Rossi, Leon Gervitz, Karthinathan Thangavelu, Gregory St John, Susan Boklage, Mark C Genovese

RMD Open Oct 2019, 5 (2) e001017; DOI: 10.1136/rmdopen-2019-001017
Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?
Denis Mongin, Kim Lauper, Carl Turesson, Merete Lund Hetland, Eirik Klami Kristianslund, Tore K Kvien, Maria Jose Santos, Karel Pavelka, Florenzo Iannone, Axel Finckh, Delphine Sophie Courvoisier

RMD Open Oct 2019, 5 (2) e000994; DOI: 10.1136/rmdopen-2019-000994
Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry
Sytske Anne Bergstra, Maura C Couto, Nimmisha Govind, Arvind Chopra, Karen Salomon Escoto, Elizabeth Murphy, Tom WJ Huizinga, Cornelia F Allaart

RMD Open Jul 2019, 5 (2) e000969; DOI: 10.1136/rmdopen-2019-000969
Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study
Joachim Sieper, Robert Landewé, Marina Magrey, Jaclyn K Anderson, Sheng Zhong, Xin Wang, Apinya Lertratanakul

RMD Open Jun 2019, 5 (1) e000917; DOI: 10.1136/rmdopen-2019-000917
Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial
Iain B McInnes, Gianfranco Ferraccioli, Maria-Antonietta D'Agostino, Manuela Le Bars, Subhashis Banerjee, Harris A Ahmad, Yedid Elbez, Philip J Mease

RMD Open May 2019, 5 (1) e000934; DOI: 10.1136/rmdopen-2019-000934
Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry
Philip J Mease, Carol J Etzel, William J Huster, Talia M Muram, April W Armstrong, Jeffrey R Lisse, Sabrina Rebello, Rhiannon Dodge, Mwangi James Murage, Jeffrey D Greenberg, William N Malatestinic

RMD Open May 2019, 5 (1) e000867; DOI: 10.1136/rmdopen-2018-000867
Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort
Manuel Francisco Ugarte-Gil, Guillermo J Pons-Estel, Luis M Vila, Gerald McGwin, Graciela S Alarcón

RMD Open May 2019, 5 (1) e000955; DOI: 10.1136/rmdopen-2019-000955
Validating 10-joint juvenile arthritis disease activity score cut-offs for disease activity levels in non-systemic juvenile idiopathic arthritis
Maria Backström, Pirjo Tynjälä, Kristiina Aalto, Minna-Maija Grönlund, Heikki Ylijoki, Anne Putto-Laurila, Johanna Kärki, Paula Keskitalo, Sirja Sard, Heini Pohjankoski, Maiju Hietanen, Silke Witter, Helena Lehto, Eliisa Löyttyniemi, Paula Vähäsalo

RMD Open Apr 2019, 5 (1) e000888; DOI: 10.1136/rmdopen-2018-000888

Main menu

Disease Activity

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Disease Activity

Pages